ATE401400T1 - Antiangiogene peptide zur behandlung oder vorbeugung von endometriose - Google Patents

Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Info

Publication number
ATE401400T1
ATE401400T1 AT04816838T AT04816838T ATE401400T1 AT E401400 T1 ATE401400 T1 AT E401400T1 AT 04816838 T AT04816838 T AT 04816838T AT 04816838 T AT04816838 T AT 04816838T AT E401400 T1 ATE401400 T1 AT E401400T1
Authority
AT
Austria
Prior art keywords
endometriosis
prevention
treatment
peptides
antiangiogenic peptides
Prior art date
Application number
AT04816838T
Other languages
English (en)
Inventor
Judah Folkman
Kashi Javaherian
Christian Becker
Amato Robert D
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE401400T1 publication Critical patent/ATE401400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
AT04816838T 2003-08-29 2004-08-30 Antiangiogene peptide zur behandlung oder vorbeugung von endometriose ATE401400T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49926403P 2003-08-29 2003-08-29
US53921304P 2004-01-26 2004-01-26

Publications (1)

Publication Number Publication Date
ATE401400T1 true ATE401400T1 (de) 2008-08-15

Family

ID=34278655

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04782583T ATE412745T1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide vom n-terminus von endostatin
AT04816838T ATE401400T1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide zur behandlung oder vorbeugung von endometriose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04782583T ATE412745T1 (de) 2003-08-29 2004-08-30 Antiangiogene peptide vom n-terminus von endostatin

Country Status (10)

Country Link
US (1) US7645735B2 (de)
EP (2) EP1687426B1 (de)
JP (2) JP2007525972A (de)
KR (1) KR20070030159A (de)
AT (2) ATE412745T1 (de)
AU (2) AU2004269399A1 (de)
CA (2) CA2537236A1 (de)
DE (2) DE602004017487D1 (de)
IL (1) IL173952A0 (de)
WO (2) WO2005021756A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
ATE412745T1 (de) 2003-08-29 2008-11-15 Childrens Medical Center Antiangiogene peptide vom n-terminus von endostatin
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
CN100398557C (zh) * 2006-04-05 2008-07-02 中国药科大学 血管生成抑制多肽及其制备方法和应用
CN100427503C (zh) * 2006-09-08 2008-10-22 哈尔滨医科大学 内皮抑制素小分子多肽及编码该多肽的核苷酸序列和互补链
ES2573253T3 (es) 2006-09-20 2016-06-06 The Board Of Regents Of The University Of Texas System Métodos para el suministro de anestésicos volátiles para anestesia regional y/o alivio del dolor
DK2244737T3 (da) 2008-01-22 2019-07-08 Univ Texas Flygtige anæstetiske sammensætninger omfattende ekstraktionsopløsningsmidler til regional anæstesi og/eller smertelindring
WO2011050311A1 (en) * 2009-10-22 2011-04-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Use of endostatin peptides for the treatment of fibrosis
EP3071325B1 (de) 2013-11-18 2021-03-03 Indian Oil Corporation Limited Verfahren zur herstellung eines katalysators zur verbesserung der flüssigkeitsausbeute in einem thermischen verkokungsverfahren
EP3071671A1 (de) 2013-11-18 2016-09-28 Indian Oil Corporation Limited Verfahren und system zur verbesserung der flüssigkeitsausbeute von schweren kohlenwasserstoffeinsätzen
CN113717274B (zh) * 2015-07-27 2023-11-28 上海贺普药业股份有限公司 一种肿瘤抑制肽
RU2711085C1 (ru) * 2019-08-12 2020-01-15 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Полипептид для ингибирования миграции и инвазии рака предстательной железы
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
CN113845582B (zh) * 2021-10-15 2022-05-27 南京市妇幼保健院 内源性多肽在制备预防或治疗子宫内膜癌靶向药物中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
KR19990066981A (ko) * 1995-10-23 1999-08-16 윌리엄 뉴우 치료용 맥관형성억제 조성물 및 방법
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
ES2224465T3 (es) * 1997-10-31 2005-03-01 Children's Medical Center Corporation Metodo para regular el tamaño y el crecimiento del tejido normal vascularizado.
DE69833794D1 (de) * 1997-12-08 2006-05-04 Beth Israel Hospital Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
US6653098B1 (en) * 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
WO1999048924A1 (en) * 1998-03-24 1999-09-30 The Children's Medical Center Corporation Endostatin derived peptides with anti-angiogenic and anti-cancer activity
WO1999062944A2 (en) * 1998-06-03 1999-12-09 The Children's Medical Center Corporation Protein oligomer compositions comprising endostatin protein and methods of using the same
AU761027B2 (en) * 1998-08-25 2003-05-29 Merck Patent Gmbh Expression and export of angiostatin and endostatin as immunofusis
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
AU4342000A (en) * 1999-04-13 2000-11-14 Merck & Co., Inc. Soluble recombinant endostatin and method of making same from (streptomyces sp)
IT1312077B1 (it) 1999-04-15 2002-04-04 Univ Degli Studi Milano Polipeptidi ad attivita' antiangiogenica.
AU4982200A (en) * 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
AU2002224403A1 (en) * 2000-10-13 2002-04-22 Entremed, Inc Endostatin and pitslre protein kinases as angiogenesis-inhibiting peptides and method of use
ITMI20010394A1 (it) * 2001-02-27 2002-08-27 Univ Degli Studi Milano Peptidi ad attivita' antiangiogenica
CA2485064A1 (en) * 2002-02-07 2003-08-14 Delta Biotechnology Limited Albumin-fused kunitz domain peptides
ATE412745T1 (de) 2003-08-29 2008-11-15 Childrens Medical Center Antiangiogene peptide vom n-terminus von endostatin
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin

Also Published As

Publication number Publication date
WO2005042566A3 (en) 2005-10-06
CA2537236A1 (en) 2005-05-12
ATE412745T1 (de) 2008-11-15
EP1668129A1 (de) 2006-06-14
IL173952A0 (en) 2006-07-05
JP2007525972A (ja) 2007-09-13
EP1687426A2 (de) 2006-08-09
US7645735B2 (en) 2010-01-12
US20060258583A1 (en) 2006-11-16
JP2007529410A (ja) 2007-10-25
EP1687426B1 (de) 2008-07-16
DE602004015142D1 (de) 2008-08-28
EP1668129B1 (de) 2008-10-29
CA2537179A1 (en) 2005-03-10
WO2005042566A2 (en) 2005-05-12
AU2004269399A1 (en) 2005-03-10
DE602004017487D1 (de) 2008-12-11
AU2004285847A1 (en) 2005-05-12
WO2005021756A1 (en) 2005-03-10
KR20070030159A (ko) 2007-03-15

Similar Documents

Publication Publication Date Title
IL173952A0 (en) Anti-angiogenic peptides and pharmaceutical compositions based thereon
ATE530560T1 (de) Vegf bindende und geträgerte peptide zur behandlung von hautkrankheiten
CY1110862T1 (el) Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης
ATE353914T1 (de) Peptide zur behandlung von tumoren und anderen bedingungen die die entfernung oder zerstörung von zelle erfordern
DE69835279D1 (de) Zusammensetzungen und verfahren zur behandlung von infektionen unter verwendung von kationischen peptiden allein oder in kombination mit antibiotika
DE60221051D1 (de) Herstellung von peptiden und proteinen durch anhäufung in vom endoplasmatischen reticulum abgeleiteten proteinkörpern
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
NZ607892A (en) Tfpi inhibitors and methods of use
ATE430161T1 (de) Peptid aus hsp70 welches nk zellaktivtät stimuliert und seine verwendung
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
ATE477272T1 (de) Verwendung von stefin a als gerüstprotein
DE602004014145D1 (de) Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen
DE60230456D1 (de) Faktor-viii-polypeptide auf hohem expressionsnivea und verwendungsverfahren
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
HUP0100267A2 (hu) Helicobacter pylori eredetű nukleinsav- és aminosav-szekvenciák és a megfelelő nukleinsavakat vagy peptideket tartalmazó vakcina-készítmények
ATE251886T1 (de) Verwendunf von apoe zum binden von tau und map2c proteinen und zur behandlung von alzheimer's krankheit
ATE356145T1 (de) Polypeptide zur regenerierung des nervensystems
DE602006017806D1 (de) Behandlung von neurodegeneration
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
NZ597470A (en) Therapeutic peptides, polypeptides ans nucleic acid sequences
DE60314289D1 (de) Synthetische peptidanaloge zur behandlung von krebs
CY1109617T1 (el) Ενα πεπτιδιο hsp70 που διεγειρει τη δραστηριοτητα φυσικων φονικων κυτταρων (νκ) και χρησεις αυτου
DE112005002912A5 (de) Pharmazeutisches Mittel umfassend Aminosäuren, Peptide, Proteine und/oder deren Bruchteile und Fragmente und deren Verwendung zur Prophylaxe und Behandlung von Defekten des Immunsystems bei Menschen und Tieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties